May CTC technologies promote better cancer management?

EPMA Journal

Volumn 6, Issue 1, 2015, Pages

  Pesta, Martin ^a   Kulda, Vlastimil ^a   Narsanska, Andrea ^a   Fichtl, Jakub ^a   Topolcan, Ondrej ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Circulating tumor cells; Colorectal cancer; PPPM; Tumor markers

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL ASSAY; CELL FUNCTION; CHEMOSENSITIVITY; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; DISEASE ACTIVITY; DISEASE MARKER; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TUMOR CELL;

EID: 84927716529     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-014-0023-x     Document Type: Article

References (84)

1. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991, 9:1749-56. 1919627.
2. Leong SP, Tseng WW. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: clinical significance and biologic implications. CA Cancer J Clin. 2014, 64:195-206. 10.3322/caac.21217, 24500995.
3. Alunni-Fabbroni M, Muller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014, 9:16-21. 10.1159/000360438, 24803882.
4. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013, 73:6384-8. 10.1158/0008-5472.CAN-13-2030, 24145355.
5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869, 14:146-9.
6. Phillips KG, Velasco CR, Li J, Kolatkar A, Luttgen M, Bethel K, et al. Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol. 2012, 2:72. 22826822.
7. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res. 2007, 13:920-8. 10.1158/1078-0432.CCR-06-1695, 17289886.
8. Zieglschmid V, Hollmann C, Gutierrez B, Albert W, Strothoff D, Gross E, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005, 25:1803-10. 16033103.
9. Galanzha EI, Zharov VP. Circulating tumor cell detection and capture by photoacoustic flow cytometry in vivo and ex vivo. Cancers (Basel). 2013, 5:1691-738. 10.3390/cancers5041691, 24335964.
10. Li P, Stratton ZS, Dao M, Ritz J, Huang TJ. Probing circulating tumor cells in microfluidics. Lab Chip. 2013, 13:602-9. 10.1039/c2lc90148j, 23306378.
11. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex Cell Search™ system. Int J Cancer. 2012, 130:1590-7. 10.1002/ijc.26111, 21469140.
12. Geng SQ, Alexandrou AT, Li JJ. Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett. 2014, 349:1-7. 10.1016/j.canlet.2014.03.036, 24727284.
13. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014, 15:178-96. 10.1038/nrm3758, 24556840.
14. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014, 3:17. 10.1186/2001-1326-3-17, 25050175.
15. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007, 171:386-95. 10.2353/ajpath.2007.070152, 17600130.
16. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994, 125:437-46. 10.1083/jcb.125.2.437, 8163559.
17. Takei H, Iino Y, Horiguchi J, Maemura M, Oyama T, Yokoe T, et al. Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol Rep. 1997, 4:33-8. 21590007.
18. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004, 10:6897-904. 10.1158/1078-0432.CCR-04-0378, 15501967.
19. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008, 123:1991-2006. 10.1002/ijc.23825, 18712708.
20. Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010, 102:1327-34. 10.1038/sj.bjc.6605651, 20389297.
21. Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. Future Oncol. 2010, 6:209-19. 10.2217/fon.09.147, 20146580.
22. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia. 2010, 15:261-73. 10.1007/s10911-010-9174-0, 20449641.
23. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012, 79:195-208. 10.1159/000337106, 22488297.
24. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011, 50:700-10. 10.3109/0284186X.2010.549151, 21261508.
25. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012, 12:178. 10.1186/1471-2407-12-178, 22591372.
26. Millner LM, Linder MW, Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013, 43:295-304. 23884225.
27. Glendenning J, Cook G. Imaging breast cancer bone metastases: current status and future directions. Semin Nucl Med. 2013, 43:317-23. 10.1053/j.semnuclmed.2013.02.002, 23725993.
28. Sree SV, Ng EY, Acharya RU, Faust O. Breast imaging: a survey. World J Clin Oncol. 2011, 2:171-8. 10.5306/wjco.v2.i4.171, 21611093.
29. Viale G. The current state of breast cancer classification. Ann Oncol. 2012, 23(Suppl 10):x207-10. 10.1093/annonc/mds326, 22987963.
30. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014, 5:412-24. 10.5306/wjco.v5.i3.412, 25114856.
31. Jalalian A, Mashohor SB, Mahmud HR, Saripan MI, Ramli AR, Karasfi B. Computer-aided detection/diagnosis of breast cancer in mammography and ultrasound: a review. Clin Imaging. 2013, 37:420-6. 10.1016/j.clinimag.2012.09.024, 23153689.
32. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010, 21:729-33. 10.1093/annonc/mdp391, 19850639.
33. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 2011, 13:R61. 10.1186/bcr2898, 21672237.
34. Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012, 14:R133. 10.1186/bcr3333, 23088337.
35. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006, 12:4218-24. 10.1158/1078-0432.CCR-05-2821, 16857794.
36. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011, 13:R67. 10.1186/bcr2907, 21699723.
37. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014, 15:406-14. 10.1016/S1470-2045(14)70069-5, 24636208.
38. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014, 106:dju066. 10.1093/jnci/dju066, 24832787.
39. Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011, 122:356-60. 10.1016/j.ygyno.2011.04.039, 21605893.
40. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014, 64:9-29. 10.3322/caac.21208, 24399786.
41. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010, 28:256-63. 10.1200/JCO.2009.23.9194, 19949015.
42. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007, 50:1783-99. 10.1007/s10350-007-9030-5, 17874269.
43. Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol. 2014, 20:6102-12. 10.3748/wjg.v20.i20.6102, 24876732.
44. Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer-a review. Eur J Surg Oncol. 2011, 37:459-65. 10.1016/j.ejso.2011.01.025, 21324632.
45. Bork U, Grützmann R, Rahbari NN, Schölch S, Distler M, Reissfelder C, et al. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014, 20:10296-304. 10.3748/wjg.v20.i30.10296, 25132746.
46. Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013, 20:2156-65. 10.1245/s10434-013-2907-8, 23456317.
47. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2:e17. 10.1371/journal.pmed.0020017, 15696205.
48. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007, 13:2890-6. 10.1158/1078-0432.CCR-06-3043, 17504988.
49. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011, 11:635-42. 10.1586/erm.11.42, 21745016.
50. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010, 17:572-8. 10.1245/s10434-009-0605-3, 19727962.
51. Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol. 2014, 20:10425-31. 10.3748/wjg.v20.i30.10425, 25132758.
52. Hayes DF, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer?. Clin Cancer Res. 2008, 14:3646-50. 10.1158/1078-0432.CCR-07-4481, 18559576.
53. Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics. 2013, 3:377-94. 10.7150/thno.5195, 23781285.
54. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006, 12:6403-9. 10.1158/1078-0432.CCR-05-1769, 17085652.
55. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009, 27:5153-9. 10.1200/JCO.2008.20.6664, 19752342.
56. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010, 21:33-9. 10.1093/annonc/mdp262, 19602564.
57. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009, 27:3303-11. 10.1200/JCO.2008.19.4423, 19451443.
58. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014..
59. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007, 9:R74. 10.1186/bcr1783, 17963511.
60. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010, 10:392-7. 10.3816/CBC.2010.n.052, 20920984.
61. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011, 128:155-63. 10.1007/s10549-011-1508-0, 21499685.
62. Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006, 12:1715-20. 10.1158/1078-0432.CCR-05-2087, 16551854.
63. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010, 124:403-12. 10.1007/s10549-010-1163-x, 20859679.
64. Ignatiadis M. Efficacy study of herceptin to treat HER2-negative CTC breast cancer (TREAT-CTC). Current Controlled Trials. 2012. http://clinicaltrials.gov/ct2/show/NCT01548677..
65. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008, 13:1270-5. 10.1634/theoncologist.2008-0181, 19056857.
66. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009, 100:1087-94. 10.1038/sj.bjc.6604848, 19293803.
67. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010, 16:790-9. 10.1158/1078-0432.CCR-09-2446, 20103678.
68. Tortola S, Steinert R, Hantschick M, Peinado MA, Gastinger I, Stosiek P, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol. 2001, 19:2837-43. 11387355.
69. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009, 15:4508-13. 10.1158/1078-0432.CCR-08-3179, 19549774.
70. Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol. 2010, 17:624-33. 10.1245/s10434-009-0831-8, 19937133.
71. Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, et al. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2013, 12:280-6. 10.1016/j.clcc.2013.06.001, 24012456.
72. Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, et al. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013, 33:3905-10. 24023327.
73. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2013, 59:252-60. 10.1373/clinchem.2012.188557, 23136247.
74. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, et al. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer. 2010, 126:2437-47. 19821489.
75. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012, 366:883-92. 10.1056/NEJMoa1113205, 22397650.
76. Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol. 2011, 13:767-73. 10.1007/s12094-011-0731-9, 22082639.
77. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007, 117:3155-63. 10.1172/JCI33295, 17975657.
78. Rudiger N, Stein E, Schill E, Spitz G, Rabenstein C, Stauch M, et al. Chemosensitivity testing of circulating epithelial tumor cells (CETC) in vitro: correlation to in vivo sensitivity and clinical outcome. J Cancer Ther. 2013, 4:597-605. 10.4236/jct.2013.42077.
79. Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol. 2007, 18:1484-92. 10.1093/annonc/mdm206, 17761704.
80. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, et al. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013, 12:2132-43. 10.4161/cc.25165, 23759587.
81. Goebel G, Zitt M, Zitt M, Müller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers. 2005, 21:105-20. 10.1155/2005/218759, 16276004.
82. González-Masiá JA, García-Olmo D, García-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013, 6:819-32. 23874104.
83. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?. EPMA J. 2013, 4:6. 10.1186/1878-5085-4-6, 23418957.
84. Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for predictive, preventive and personalised medicine. EPMA J 2012, 3:14. 10.1186/1878-5085-3-14, 23116135.